ABCA1 and Alzheimer disease: Therefore, activation of the LXR/RXR or inactivation of the SREBP2 pathway by inhibiting miR-33a both offer possible therapeutic possibilities for Alzheimer’s disease, by increasing the expression of ABCA1.